4:02 pm BIND Therapeutics presents clinical data highlighting unique attributes of lead cancer drug candidate, BIND-014, at AACR 2014 Annual Meeting; results demonstrated increased dose intensity of weekly dosing vs. every three week dosing – HedgeChatter

4:02 pm BIND Therapeutics presents clinical data highlighting unique attributes of lead cancer drug candidate, BIND-014, at AACR 2014 Annual Meeting; results demonstrated increased dose intensity of weekly dosing vs. every three week dosing

08 Apr

4:02 pm BIND Therapeutics presents clinical data highlighting unique attributes of lead cancer drug candidate, BIND-014, at AACR 2014 Annual Meeting; results demonstrated increased dose intensity of weekly dosing vs. every three week dosing

Bystocknews BIND, stock Comments Off

View todays social media effects on BIND

View the latest stocks trending across Twitter. Click to view dashboard

See who BIND is hiring next, click here to view

Author